Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100® and VerifyNow®
Background: The prevalence of ex vivo high on-treatment platelet reactivity (HTPR) to commonly prescribed antiplatelet regimens after transient ischemic attack (TIA) or ischemic stroke is uncertain.Methods: Platelet function inhibition was simultaneously assessed with modified light transmission aggregometry (VerifyNow; Accumetrics Inc, San Diego, CA) and with a moderately high shear stress platelet function analyzer (PFA-100; Siemens Medical Solutions USA, Inc, Malvern, PA) in a pilot, cross-sectional study of TIA or ischemic stroke patients. Patients were assessed on aspirin–dipyridamole combination therapy (n = 51) o...
Source: Journal of Stroke and Cerebrovascular Diseases - September 14, 2012 Category: Neurology Authors: Justin A. Kinsella, W. Oliver Tobin, Dermot Cox, Tara Coughlan, Ronan Collins, Desmond O’Neill, Raymond P. Murphy, Dominick J.H. McCabe Tags: Original Articles Source Type: research

Hemorrhagic Risk of Emergent Endovascular Treatment Plus Stenting in Patients with Acute Ischemic Stroke
Conclusions: Our findings suggest that emergent stenting in endovascular treatment of AIS is associated with SICH.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2013 Category: Neurology Authors: Laura Dorado, Carlos Castaño, Mònica Millán, Aitziber Aleu, Natàlia Pérez de la Ossa, Meritxell Gomis, Elena López-Cancio, Elio Vivas, Ana Rodriguez-Campello, Mar Castellanos, Antoni Dávalos Tags: Original Articles Source Type: research

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol.
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research

Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure Clinical Sciences
Conclusion— Among HF patients in ACTIVE, neither the presence of LVSD or degree of symptom severity influenced risk of embolic events.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Sandhu, R. K., Hohnloser, S. H., Pfeffer, M. A., Yuan, F., Hart, R. G., Yusuf, S., Connolly, S. J., McAlister, F. A., Healey, J. S. Tags: Congestive, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke Clinical Sciences Source Type: research

Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study
The measurement of platelet reactivity in patients with stroke undergoing antiplatelet therapies is not commonly performed in clinical practice. We assessed the prevalence of therapy responsiveness in patients with stroke and further investigated differences between patients on prevention therapy at stroke onset and patients naive to antiplatelet medications. We also sought differences in responsiveness between etiological subtypes and correlations between Clopidogrel responsiveness and genetic polymorphisms.
Source: Journal of Stroke and Cerebrovascular Diseases - May 30, 2017 Category: Neurology Authors: Francesca Rosafio, Nicoletta Lelli, Stefano Mimmi, Laura Vandelli, Guido Bigliardi, Maria Luisa Dell'Acqua, Livio Picchetto, Roberta Pentore, Diana Ferraro, Tommaso Trenti, Paolo Nichelli, Andrea Zini Source Type: research

Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response
Antiplatelet therapy is a cornerstone prevention strategy for secondary ischemic stroke (IS) and transient ischemic attack (TIA). Yet, a proportion of patients who receive antiplatelet therapy experience recurrent ischemic cerebrovascular events. A recent meta-analysis found an increased risk of recurrent stroke in clopidogrel- or aspirin-treated patients with ischemic stroke who had high on-treatment platelet reactivity (HTPR). Few studies have focused specifically on clopidogrel HTPR. Therefore, the aim of this study was to examine the relationship between clopidogrel HTPR and recurrent ischemic events in a population of...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2018 Category: Neurology Authors: Charlotte L ützhøft Rath, Niklas Rye Jørgensen, Troels Wienecke Source Type: research

Drug Combo Cuts Stroke Risk After TIA
A simple combination of two anti-clotting drugs, clopidogrel and aspirin, can cut the risk of a stroke in patients who have already experienced a mini-stroke or transient ischemic attack (TIA). This was the result of a phase 3 clinical trial conducted in China with the help of a US physician who says it could change the standard of care in the US. The investigators report their findings in the 26 June online issue of the New England Journal of Medicine, NEJM. The trial took place at several sites in China and was designed in partnership with S...
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Risk Of Stroke Effectively Reduced By Simple 2-Drug Combination
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs - clopidogrel and aspirin- lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks. Described this week in the New England Journal of Medicine (July 4, 2013 print issue), the clinical trial was conducted at multiple sites in China and designed in partnership with a physician at UC San Francisco...
Source: Health News from Medical News Today - June 28, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen
This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day). Platelet function was measured using 3 different “point-of-care” platelet function analyzers: the Thrombelastograph hemostasis system, the Accumetrics VerifyNow system, and the Chronolog 570VS impedance aggregometer. Platelet function was assessed before administration of a 300-mg CPG loading dose and again at 26 hours and 64 hours after this loading dose along with a 75-mg daily maintenance dose. All 3 instruments detected marked ...
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2011 Category: Neurology Authors: Zohara Sternberg, Marilou Ching, Robert N. Sawyer, Trevor Chichelli, Fan Li, David Janicke, Vladan Radovic, Bijal Mehta, Osman Farooq, Frederick E. Munschauer Tags: Original Articles Source Type: research

Dual antiplatelet therapy in recurrent stroke prevention: do the benefits outweigh the risks?
This study assessed seven randomised controlled trials, comprising 39 574 patients and comparing dual versus single antiplatelet therapies. Medications used included aspirin (50–325 mg daily), clopidogrel (75 mg daily), aspirin plus dipyridamole (50/400 mg daily) and ticlopidine (100 mg daily). Patients had a history of ischaemic stroke (three trials) or TIA (four...
Source: Evidence-Based Medicine - July 18, 2014 Category: Internal Medicine Authors: Farooq, M. U., Gorelick, P. B. Tags: Clinical trials (epidemiology), Stroke Therapeutics Source Type: research

Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial Clinical Sciences
Conclusions— Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain. Clinical Trial Registration— URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Sharma, M., Pearce, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., Coffey, C. S., Hart, R. G. Tags: Cerebral Lacunes, Antiplatelets Clinical Sciences Source Type: research

Predictive Value of High Residual Platelet Reactivity by Flow Cytometry for Outcomes of Ischemic Stroke Patients on Clopidogrel Therapy
High residual platelet reactivity (HRPR) assessed by multiple tests has been associated with worse clinical outcomes. However, the clinical impact of HRPR assessed by flow cytometry is unknown. The aim of this study was to validate the predictive value of HRPR measured by flow cytometry for clinical outcomes in ischemic stroke patients during clopidogrel therapy. Overall, 198 consecutive patients with ischemic stroke taking clopidogrel underwent platelet function testing on flow cytometer including adenosine diphosphate (ADP)–induced platelet aggregation (PAg) and platelet activation markers (CD62P, CD63, and PAC-1).
Source: Journal of Stroke and Cerebrovascular Diseases - April 10, 2015 Category: Neurology Authors: Li-Na Qiu, Lin Wang, Xin Li, Rui-Fa Han, Xiao-Shuang Xia, Jie Liu Source Type: research

Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke
Background: To explore the association of platelet activation markers, vitamin D, and antiplatelet drugs resistance in ischemic stroke patients. Methods: A total of 230 patients with ischemic stroke were enrolled in this study. Platelet aggregation, platelet activation marker (CD62p), and vitamin D were measured after 7-14 days of dual antiplatelet treatment (aspirin  + clopidogrel). All individuals were divided into a drug resistance group and a drug sensitive group according to the platelet maximum aggregation rate induced by antagonist adenosine diphosphate or arachidonic acid.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2019 Category: Neurology Authors: Bi-Chao Lu, Xiao-Jie Shi, Lin Liang, Na Dong, Zhi-Zhong Liu Source Type: research

Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke
The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial.
Source: Journal of Stroke and Cerebrovascular Diseases - February 6, 2020 Category: Neurology Authors: Scott E. Kasner, Bryan Randall, Grethe Andersen, Helle K. Iversen, Risto Roine, Christina Sjostrand, John F. Rhodes, Lars S øndergaard, The Gore REDUCE Study Investigators Source Type: research

Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic stroke patients treated with clopidogrel in China: A meta-analysis
The relationship between CYP2C19 *2,*3 gene variants and the recurrence in ischemic stroke patients treated with clopidogrel is still controversial according to the available published literature. To evaluate correlations between  CYP2C19 *2,*3 gene variants, metabolic typing according to *2, *3 SNPs (the polymorphism of rs4244285, rs4986893) and stroke recurrence, we performed this study through meta-analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2022 Category: Neurology Authors: Yu Yan, Ruixiao Hao, Xiuyuan Zhao, Xiaoshuang Xia, Lin Wang, Xin Li Source Type: research